These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10496304)

  • 21. Application of preformed hammerhead ribozymes in the gene therapy of cancer (review).
    Sioud M
    Int J Mol Med; 1999 Apr; 3(4):381-4. PubMed ID: 10085409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene-expressed RNA as a therapeutic: issues to consider, using ribozymes and small hairpin RNA as specific examples.
    Fanning GC; Symonds G
    Handb Exp Pharmacol; 2006; (173):289-303. PubMed ID: 16594621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense makes sense in engineered regenerative medicine.
    Yao Y; Wang C; Varshney RR; Wang DA
    Pharm Res; 2009 Feb; 26(2):263-75. PubMed ID: 19015958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisense approaches to cancer gene therapy.
    Mercola D; Cohen JS
    Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oligonucleotide-based antiviral strategies.
    Schubert S; Kurreck J
    Handb Exp Pharmacol; 2006; 173(173):261-87. PubMed ID: 16594620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic oligonucleotides.
    Goodchild J
    Methods Mol Biol; 2011; 764():1-15. PubMed ID: 21748630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense treatment of viral infection.
    Whitton JL
    Adv Virus Res; 1994; 44():267-303. PubMed ID: 7817875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Message therapy: gene therapy that targets mRNA sequence and stability.
    Kozarsky KF; Couture LA
    Am J Hum Genet; 1997 Oct; 61(4):790-4. PubMed ID: 9382086
    [No Abstract]   [Full Text] [Related]  

  • 29. Antisense oligonucleotides for haematological malignancies.
    Cotter FE
    Haematologica; 1999 Jun; 84 Suppl EHA-4():19-22. PubMed ID: 10907458
    [No Abstract]   [Full Text] [Related]  

  • 30. Strategies to identify potential therapeutic target sites in RNA.
    Lützelberger M; Kjems J
    Handb Exp Pharmacol; 2006; (173):243-59. PubMed ID: 16594619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants.
    von Weizsäcker F; Wieland S; Köck J; Offensperger WB; Offensperger S; Moradpour D; Blum HE
    Hepatology; 1997 Aug; 26(2):251-5. PubMed ID: 9252130
    [No Abstract]   [Full Text] [Related]  

  • 32. Progress and Prospects of Anti-HBV Gene Therapy Development.
    Maepa MB; Roelofse I; Ely A; Arbuthnot P
    Int J Mol Sci; 2015 Jul; 16(8):17589-610. PubMed ID: 26263978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ribozyme and peptide-nucleic acid-based gene therapy.
    Phylactou LA
    Adv Drug Deliv Rev; 2000 Nov; 44(2-3):97-108. PubMed ID: 11072108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
    Tabler M; Homann M; Tzortzakaki S; Sczakiel G
    Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular uptake properties of a 2'-amino/2'-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA.
    Fell PL; Hudson AJ; Reynolds MA; Usman N; Akhtar S
    Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):319-26. PubMed ID: 9303183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular therapy for renal diseases.
    Lipkowitz MS; Klotman ME; Bruggeman LA; Nicklin P; Hanss B; Rappaport J; Klotman PE
    Am J Kidney Dis; 1996 Oct; 28(4):475-92. PubMed ID: 8840936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths?
    Akhtar S; Rossi JJ
    J Antimicrob Chemother; 1996 Aug; 38(2):159-65. PubMed ID: 8877530
    [No Abstract]   [Full Text] [Related]  

  • 38. Nucleic-acid therapeutics: basic principles and recent applications.
    Opalinska JB; Gewirtz AM
    Nat Rev Drug Discov; 2002 Jul; 1(7):503-14. PubMed ID: 12120257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense technologies have a future fighting neurodegenerative diseases.
    Seidman S; Eckstein F; Grifman M; Soreq H
    Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):333-40. PubMed ID: 10463077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
    Cucco C; Calabretta B
    Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.